JOURNAL 2651


Organic Communications
VOLUME & ISSUE
Year: 2022 Issue: 4 October-December
PAGES
p.356 - 377
STATISTICS
Viewed 136 times.
AUTHORS
  • İlker Demirbolat
  • Necla Kulabaş
  • Merve Gürboğa
  • Özlem Bingöl Özakpınar
  • Gamze Çiftçi
  • Kemal Yelekçi
  • Jianyang Liu
  • Per-Johan Jakobsson
  • Özkan Danış
  • Ayşe Ogan
  • İlkay Küçükgüzel
PDF OF ARTICLE

GRAPHICAL ABSTRACT


ABSTRACT


Some novel triazole-bearing acetamide derivatives 9-26 were synthesized starting from carvacrol. All synthesized compounds were characterized by FTIR, 1H-NMR, 13C-NMR, HMBC and MS data. In vitro cytotoxic activities of all synthesized molecules against five cancer lines (human breast cancer MCF-7, human lung cancer A549, human prostate cancer PC-3, human chronic myelogenous leukemia K562, human neuroblastoma SH-SY5Y cell lines) were evaluated by MTT assay. Compounds were also tested on mouse embryonic fibroblast cells (NIH/3T3) to determine selectivity. Eighteen target compounds 9-26 were screened for their mPGES-1 and COX-1/2 inhibitory activities. Of these compounds, 26 (KUC16D425) showed the highest mPGES-1 inhibition at 10 µM. This compound have also been observed to induce apoptosis and inhibit cell migration in MCF-7 cells. In silico molecular docking calculations were performed to understand the binding interactions of compounds with target proteins. ADMET predictions were also done to evaluate drug-like properties of the novel compounds.

KEYWORDS
  • Carvacrol
  • 1,2,4-triazoles
  • cancer
  • apoptosis
  • mPGES-1
  • in silico studies

SUPPORTING INFORMATION


Supporting Information
Download File A5-142-OC-2212-2651-SI.pdf (3.9 MB)